CSI and Aerolase to Codevelop Laser Atherectomy Technology
July 31, 2018—Cardiovascular Systems, Inc. (CSI) announced that it has signed an agreement with Aerolase Corporation to codevelop a new laser atherectomy device for treating multiple forms of arterial disease. The collaboration seeks to improve the care of patients with peripheral arterial disease and in-stent restenosis.
Aerolase’s laser technology is currently cleared by the FDA for dermatology and medical aesthetic uses. Under the terms of the agreement, CSI made an equity investment of an undisclosed value in Aerolase and will make additional equity investments as development milestones are met.